Insight into the structural requirements of gelatinases (MMP-2 and MMP-9) inhibitors by multiple validated molecular modelling approaches: Part II

References

• X. Wang and R.A. Khalil, Matrix metalloproteinases, vascular remodeling, and vascular disease, Adv. Pharmacol. 81 (2018), pp. 241–330. doi:https://doi.org/10.1016/bs.apha.2017.08.002.
   PubMedGoogle Scholar
• S.K. Baidya, S.A. Amin, and T. Jha, Outline of gelatinase inhibitors as anti-cancer agents: A patent mini-review for 2010-present, Eur. J. Med. Chem. 213 (2021), pp. 113044. doi:https://doi.org/10.1016/j.ejmech.2020.113044.
   PubMed Web of Science ®Google Scholar
• H. Laronha and J. Caldeira, Structure and function of human matrix metalloproteinases, Cells 9 (2020), pp. 1076. doi:https://doi.org/10.3390/cells9051076.
   PubMed Web of Science ®Google Scholar
• N. Cui, M. Hu, and R.A. Khalil, Biochemical and biological attributes of matrix metalloproteinases, Prog. Mol. Biol. Trans. Sci. 147 (2017), pp. 1–73. doi:https://doi.org/10.1016/bs.pmbts.2017.02.005.
   PubMed Web of Science ®Google Scholar
• K. Li, F.R. Tay, and C.K.Y. Yiu, The past, present and future perspectives of matrix metalloproteinase inhibitors, Pharmacol. Ther. 207 (2020), pp. 107465. doi:https://doi.org/10.1016/j.pharmthera.2019.107465.
   PubMed Web of Science ®Google Scholar
• G.B. Fields, The rebirth of matrix metalloproteinase inhibitors: Moving beyond the dogma, Cells 8 (2019), pp. 984. doi:https://doi.org/10.3390/cells8090984.
   PubMed Web of Science ®Google Scholar
• J.Y. Choi, R. Fuerst, A.M. Knapinska, A.B. Taylor, L. Smith, X. Cao, P.J. Hart, G.B. Fields, and W.R. Roush, Structure-based design and synthesis of potent and selective matrix metalloproteinase 13 inhibitors, J. Med. Chem. 60 (2017), pp. 5816–5825. doi:https://doi.org/10.1021/acs.jmedchem.7b00514.
   PubMed Web of Science ®Google Scholar
• E. Nuti, D. Cuffaro, F. D’Andrea, L. Rosalia, L. Tepshi, M. Fabbi, G. Carbotti, S. Ferrini, S. Santamaria, C. Camodeca, L. Ciccone, E. Orlandini, S. Nencetti, E.A. Stura, V. Dive, and A. Rossello, Sugar-based arylsulfonamide carboxylates as selective and water-soluble matrix metalloproteinase-12 inhibitors, ChemMedChem 11 (2016), pp. 1626–1637. doi:https://doi.org/10.1002/cmdc.201600235.
   PubMed Web of Science ®Google Scholar
• L. Devel, V. Rogakos, A. David, A. Makaritis, F. Beau, P. Cuniasse, A. Yiotakis, and V. Dive, Development of selective inhibitors and substrate of matrix metalloproteinase-12, J. Biol. Chem. 281 (2006), pp. 11152–11160. doi:https://doi.org/10.1074/jbc.M600222200.
   PubMed Web of Science ®Google Scholar
• R.H. Scannevin, R. Alexander, T.M. Haarlander, S.L. Burke, M. Singer, C. Huo, Y.M. Zhang, D. Maguire, J. Spurlino, I. Deckman, K.I. Carroll, F. Lewandowski, E. Devine, K. Dzordzorme, B. Tounge, C. Milligan, S. Bayoumy, R. Williams, C. Schalk-Hihi, K. Leonard, P. Jackson, M. Todd, L.C. Kuo, and K.J. Rhodes, Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation, J. Biol. Chem. 292 (2017), pp. 17963–17974. doi:https://doi.org/10.1074/jbc.M117.806075.
   PubMed Web of Science ®Google Scholar
• P. Sarkar, Z. Li, W. Ren, S. Wang, S. Shao, J. Sun, X. Ren, N.G. Perkins, Z. Guo, C.A. Chang, J. Song, and M. Xue, Inhibiting matrix metalloproteinase-2 activation by perturbing protein-protein interactions using a cyclic peptide, J. Med. Chem. 63 (2020), pp. 6979–6990. doi:https://doi.org/10.1021/acs.jmedchem.0c00180.
   PubMed Web of Science ®Google Scholar
• B. Pijet, A. Konopka, E. Rejmak, M. Stefaniuk, D. Khomiak, E. Bulska, S. Pikul, and L. Kaczmarek, The matrix metalloproteinase inhibitor marimastat inhibits seizures in a model of kainic acid-induced status epilepticus, Sci. Rep. 10 (2020), pp. 21314. .
   PubMed Web of Science ®Google Scholar
• R.P. Iyer, N.L. Patterson, G.B. Fields, and M.L. Lindsey, The history of matrix metalloproteinases: Milestones, myths, and misperceptions, Am. J. Physiol. Heart Circ. Physiol. 303 (2012), pp. H919–H930. doi:https://doi.org/10.1152/ajpheart.00577.2012.
   PubMed Web of Science ®Google Scholar
• A. Winer, S. Adams, and P. Mignatti, Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes, Mol. Cancer Ther. 17 (2018), pp. 1147–1155. doi:https://doi.org/10.1158/1535-7163.
   PubMed Web of Science ®Google Scholar
• G. Gonzalez-Avila, B. Sommer, D.A. Mendoza-Posada, C. Ramos, A.A. Garcia-Hernandez, and R. Falfan-Valencia, Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer, Crit. Rev. Oncol. Hematol. 137 (2019), pp. 57–83. doi:https://doi.org/10.1016/j.critrevonc.2019.02.010.
   PubMed Web of Science ®Google Scholar
• G.B. Fields, Mechanisms of action of novel drugs targeting angiogenesis-promoting matrix metalloproteinases, Front. Immunol. 10 (2019), pp. 1278. doi:https://doi.org/10.3389/fimmu.2019.01278.
   PubMed Web of Science ®Google Scholar
• M. Toth and R. Fridman, Assessment of gelatinases (MMP-2 and MMP-9) by gelatin zymography, Meth. Mol. Med. 57 (2001), pp. 163–174. doi:https://doi.org/10.1385/1-59259-136-1:163.
   PubMedGoogle Scholar
• M. Gooyit, W. Song, K.V. Mahasenan, K. Lichtenwalter, M.A. Suckow, V.A. Schroeder, W.R. Wolter, S. Mobashery, and M. Chang, O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier, J. Med. Chem. 56 (2013), pp. 8139–8150. doi:https://doi.org/10.1021/jm401217d.
   PubMed Web of Science ®Google Scholar
• R.D. Bonfil, A. Sabbota, S. Nabha, M.M. Bernardo, Z. Dong, H. Meng, H. Yamamoto, S.R. Chinni, I.T. Lim, M. Chang, L.C. Filetti, S. Mobashery, M.L. Cher, and R. Fridman, Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor, Int. J. Cancer 118 (2006), pp. 2721–2726. doi:https://doi.org/10.1002/ijc.21645.
   PubMed Web of Science ®Google Scholar
• A. Krüger, M.J. Arlt, M. Gerg, C. Kopitz, M.M. Bernardo, M. Chang, S. Mobashery, and R. Fridman, Antimetastatic activity of a novel mechanism-based gelatinase inhibitor, Cancer Res. 65 (2005), pp. 3523–3526. doi:https://doi.org/10.1158/0008-5472.CAN-04-3570.
   PubMed Web of Science ®Google Scholar
• N. Adhikari, A.K. Halder, S. Mallick, A. Saha, K.D. Saha, and T. Jha, Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays, Bioorg. Med. Chem. 24 (2016), pp. 4291–4309. doi:https://doi.org/10.1016/j.bmc.2016.07.023.
   PubMed Web of Science ®Google Scholar
• A. Mukherjee, N. Adhikari, and T. Jha, A pentanoic acid derivative targeting matrix metalloproteinase-2 (MMP-2) induces apoptosis in a chronic myeloid leukemia cell line, Eur. J. Med. Chem. 141 (2017), pp. 37–50. doi:https://doi.org/10.1016/j.ejmech.2017.09.052.
   PubMed Web of Science ®Google Scholar
• S. Das, S.A. Amin, S. Datta, N. Adhikari, and T. Jha, Synthesis, biological activity, structure activity relationship study and liposomal formulation development of some arylsulfonyl pyroglutamic acid derivatives, J. Mol. Struct. 1248 (2022), pp. 131512. doi:https://doi.org/10.1016/j.molstruc.2021.131512.
   Web of Science ®Google Scholar
• S. Das, S.A. Amin, and T. Jha, Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies, Eur. J. Med. Chem. 223 (2021), pp. 113623. doi:https://doi.org/10.1016/j.ejmech.2021.113623.
   PubMed Web of Science ®Google Scholar
• A. Gimeno, R. Beltrán-Debón, M. Mulero, G. Pujadas, and S. Garcia-Vallvé, Understanding the variability of the S1’ pocket to improve matrix metalloproteinase inhibitor selectivity profiles, Drug. Discov. Today 25 (2020), pp. 38–57. doi:https://doi.org/10.1016/j.drudis.2019.07.013.
   PubMed Web of Science ®Google Scholar
• S. Das, S.A. Amin, and T. Jha, Insight into the structural requirement of aryl sulphonamide based gelatinases (MMP-2 and MMP-9) inhibitors - Part I: 2D-QSAR, 3D-QSAR topomer CoMFA and Naïve Bayes studies - First report of 3D-QSAR Topomer CoMFA analysis for MMP-9 inhibitors and jointly inhibitors of gelatinases together, SAR QSAR Environ. Res. 32 (2021), pp. 655–687. doi:https://doi.org/10.1080/1062936X.2021.1955414.
   PubMed Web of Science ®Google Scholar
• M.A. Santos, S.M. Marques, T. Tuccinardi, P. Carelli, L. Panelli, and A. Rossello, Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors, Bioorg. Med. Chem. 14 (2006), pp. 7539–7550. doi:https://doi.org/10.1016/j.bmc.2006.07.011.
   PubMedGoogle Scholar
• A. Biasone, P. Tortorella, C. Campestre, M. Agamennone, S. Preziuso, M. Chiappini, E. Nuti, P. Carelli, A. Rossello, F. Mazza, and C. Gallina, α-Biphenylsulfonylamino 2-methylpropyl phosphonates: Enantioselective synthesis and selective inhibition of MMPs, Bioorg. Med. Chem. 15 (2007), pp. 791–799. .
   PubMed Web of Science ®Google Scholar
• E. Nuti, E. Orlandini, S. Nencetti, A. Rossello, A. Innocenti, A. Scozzafava, and C.T. Supuran, Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with sulfonylated hydroxamates, Bioorg. Med. Chem. 15 (2007), pp. 2298–2311. .
   PubMed Web of Science ®Google Scholar
• S.M. Marques, E. Nuti, A. Rossello, C.T. Supuran, T. Tuccinardi, A. Martinelli, and M.A. Santos, Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: Iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates, J. Med. Chem. 51 (2008), pp. 7968–7979. doi:https://doi.org/10.1021/jm800964f.
   PubMed Web of Science ®Google Scholar
• M.T. Rubino, M. Agamennone, C. Campestre, G. Fracchiolla, A. Laghezza, F. Loiodice, E. Nuti, A. Rossello, and P. Tortorella, Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors, ChemMedChem 4 (2009), pp. 352–362. doi:https://doi.org/10.1002/cmdc.200800324.
   PubMed Web of Science ®Google Scholar
• E. Nuti, F. Casalini, S.I. Avramova, S. Santamaria, G. Cercignani, L. Marinelli, V. La Pietra, E. Novellino, E. Orlandini, S. Nencetti, T. Tuccinardi, A. Martinelli, N.H. Lim, R. Visse, H. Nagase, and A. Rossello, N-O-Isopropyl sulfonamido-based hydroxamates: Design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis, J. Med. Chem. 52 (2009), pp. 4757–4773. doi:https://doi.org/10.1021/jm900261f.
   PubMed Web of Science ®Google Scholar
• E. Nuti, L. Panelli, F. Casalini, S.I. Avramova, E. Orlandini, S. Santamaria, S. Nencetti, T. Tuccinardi, A. Martinelli, G. Cercignani, N. D’Amelio, A. Maiocchi, F. Uggeri, and A. Rossello, Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors, J. Med. Chem. 52 (2009), pp. 6347–6361. doi:https://doi.org/10.1021/jm900335a.
   PubMed Web of Science ®Google Scholar
• E. Nuti, F. Casalini, S.I. Avramova, S. Santamaria, M. Fabbi, S. Ferrini, L. Marinelli, V. La Pietra, V. Limongelli, E. Novellino, G. Cercignani, E. Orlandini, S. Nencetti, and A. Rossello, Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models, J. Med. Chem. 53 (2010), pp. 2622–2635. doi:https://doi.org/10.1021/jm901868z.
   PubMed Web of Science ®Google Scholar
• E. Nuti, F. Casalini, S. Santamaria, P. Gabelloni, S. Bendinelli, E. Da Pozzo, B. Costa, L. Marinelli, V. La Pietra, E. Novellino, M.M. Bernardo, R. Fridman, F. Da Settimo, C. Martini, and A. Rossello, Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors, Eur. J. Med. Chem. 46 (2011), pp. 2617–2629. .
   PubMed Web of Science ®Google Scholar
• E. Nuti, A.R. Cantelmo, C. Gallo, A. Bruno, B. Bassani, C. Camodeca, T. Tuccinardi, L. Vera, E. Orlandini, S. Nencetti, E.A. Stura, A. Martinelli, V. Dive, A. Albini, and A. Rossello, N-O-Isopropyl Sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors: Hit selection and in vivo antiangiogenic activity, J. Med. Chem. 58 (2015), pp. 7224–7240. doi:https://doi.org/10.1021/acs.jmedchem.5b00367.
   PubMed Web of Science ®Google Scholar
• E. Nuti, D. Cuffaro, E. Bernardini, C. Camodeca, L. Panelli, S. Chaves, L. Ciccone, L. Tepshi, L. Vera, E. Orlandini, S. Nencetti, E.A. Stura, M.A. Santos, V. Dive, and A. Rossello, Development of thioaryl-based matrix metalloproteinase-12 inhibitors with alternative zinc-binding groups: Synthesis, potentiometric, NMR, and crystallographic studies, J. Med. Chem. 61 (2018), pp. 4421–4435. doi:https://doi.org/10.1021/acs.jmedchem.8b00096.
   PubMed Web of Science ®Google Scholar
• ChemDraw Ultra 5.0, Cambridge Soft Corporation, USA, 2010. Software available at https://cs-chemdraw-ultra.software.informer.com/5.0/ Accessed 9th March 2022.
   Google Scholar
• Discovery Studio 3.0, Accelrys Inc., San Diego, USA, 2015; Software available at http://www.accelrys.com Accessed 9th March 2022.
   Google Scholar
• L. Chen, Y. Li, Q. Zhao, H. Peng, and T. Hou, ADME evaluation in drug discovery. 10. Predictions of P-glycoprotein inhibitors using recursive partitioning and naive Bayesian classification techniques, Mol. Pharm. 8 (2011), pp. 889–900. doi:https://doi.org/10.1021/mp100465q.
   PubMed Web of Science ®Google Scholar
• K. Ghosh, B. Bhardwaj, S.A. Amin, T. Jha, and S. Gayen, Identification of structural fingerprints for ABCG2 inhibition by using Monte Carlo optimization, Bayesian classification, and structural and physicochemical interpretation (SPCI) analysis, SAR QSAR Environ. Res. 31 (2020), pp. 439–455. doi:https://doi.org/10.1080/1062936X.2020.1771769.
   PubMed Web of Science ®Google Scholar
• C.W. Yap, PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints, J. Comput. Chem. 32 (2011), pp. 1466–1474. doi:https://doi.org/10.1002/jcc.21707.
   PubMed Web of Science ®Google Scholar
• F. Sadeghi, A. Afkhami, T. Madrakian, and R. Ghavami, Computational study on subfamilies of piperidine derivatives: QSAR modelling, model external verification, the inter-subset similarity determination, and structure-based drug designing, SAR QSAR Environ. Res. 32 (2021), pp. 433–462. doi:https://doi.org/10.1080/1062936X.2021.1891568.
   PubMed Web of Science ®Google Scholar
• QSAR Tools, DTC Laboratory, India, 2015; Software available at https://dtclab.webs.com/software-tools accessed 22nd January 2021.
   Google Scholar
• A. Golbraikh and A. Tropsha, Beware of q2!, J. Mol. Graph Model. 20 (2002), pp. 269–276. doi:https://doi.org/10.1016/s1093-3263(01)00123-1.
   PubMed Web of Science ®Google Scholar
• V.N. Vapnik, The Nature of Statistical Learning Theory, 2nd ed., Springer, New York, 2000.
   Google Scholar
• C. Nantasenamat, A. Worachartcheewan, S. Prachayasittikul, C. Isarankura-Na-Ayudhya, and V. Prachayasittikul, QSAR modeling of aromatase inhibitory activity of 1-substituted 1,2,3-triazole analogs of letrozole, Eur. J. Med. Chem. 69 (2013), pp. 99–114. doi:https://doi.org/10.1016/j.ejmech.2013.08.015.
   PubMed Web of Science ®Google Scholar
• D. Kovács, P. Király, and G. Tóth, Sample-size dependence of validation parameters in linear regression models and in QSAR, SAR QSAR Environ. Res 32 (2021), pp. 247–268. doi:https://doi.org/10.1080/1062936X.2021.1890208.
   PubMed Web of Science ®Google Scholar
• E. Pourbasheer, R. Aalizadeh, and M.R. Ganjali, QSAR study of CK2 inhibitors by GA-MLR and GA-SVM methods, Arabian J. Chem. 12 (2019), pp. 2141–2149. doi:https://doi.org/10.1016/j.arabjc.2014.12.021.
   Web of Science ®Google Scholar
• E. Pourbasheer, R. Aalizadeh, M.R. Ganjali, and P. Norouzi, QSAR study of a1b4 integrin inhibitors by GA-MLR and GA-SVM methods, Struct. Chem 25 (2014), pp. 355–370. doi:https://doi.org/10.1007/s11224-013-0300-7.
   Web of Science ®Google Scholar
• K. Roy, D.K. Pal, A.U. De, and C. Sengupta, QSAR of matrix metalloproteinase inhibitor N-[(substituted phenyl)sulfonyl]-N-4-nitrobenzylglycine hydroxamates using LFER model, Drug Des. Discov. 17 (2001), pp. 315–323.
   PubMedGoogle Scholar
• D. Kumar and S.P. Gupta, A quantitative structure–activity relationship study on some matrix metalloproteinase and collagenase inhibitors, Bioorg. Med. Chem. 11 (2003), pp. 421–426. doi:https://doi.org/10.1016/s0968-0896(02)00438-8.
   PubMed Web of Science ®Google Scholar
• S.P. Gupta, D. Kumar, and S. Kumaran, A quantitative structure–activity relationship study of hydroxamate matrix metalloproteinase inhibitors derived from funtionalized 4-aminoprolines, Bioorg. Med. Chem. 11 (2003), pp. 1975–1981. doi:https://doi.org/10.1016/s0968-0896(03)00069-5.
   PubMed Web of Science ®Google Scholar
• S.P. Gupta, V. Maheswaran, V. Pande, and D. Kumar, A comparative QSAR study on carbonic anhydrase and matrix metalloproteinase inhibition by sulfonylated amino acid hydroxamates, J. Enz. Inhib. Med. Chem. 18 (2003), pp. 7–13. doi:https://doi.org/10.1080/1475636021000049735.
   PubMed Web of Science ®Google Scholar
• M. Fernández, J. Caballero, and A. Tundidor-Camba, Linear and nonlinear QSAR study of N-hydroxy-2-[(phenylsulfonyl)amino]acetamide derivatives as matrix metalloproteinase inhibitors, Bioorg. Med. Chem. 14 (2006), pp. 4137–4150. doi:https://doi.org/10.1016/j.bmc.2006.01.072.
   PubMed Web of Science ®Google Scholar
• S.P. Gupta and S. Kumaran, Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: Hydroxamic acid analogs, Med. Chem. 2 (2006), pp. 243–250. doi:https://doi.org/10.2174/157340606776930790.
   PubMedGoogle Scholar
• R.P. Verma and C. Hansch, Matrix metalloproteinases (MMPs): Chemical-biological functions and (Q)SARs, Bioorg, Med. Chem. 15 (2007), pp. 2223–2268. doi:https://doi.org/10.1016/j.bmc.2007.01.011.
   Web of Science ®Google Scholar
• O. Nicolotti, M. Catto, I. Giangreco, M. Barletta, F. Leonetti, A. Stefanachi, L. Pisani, S. Cellamare, P. Tortorella, F. Loiodice, and A. Carotti, Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9, Eur. J. Med. Chem. 58 (2012), pp. 368–376. doi:https://doi.org/10.1016/j.ejmech.2012.09.036.
   PubMed Web of Science ®Google Scholar
• R.P. Verma, A. Kurup, and C. Hansch, On the role of polarizability in QSAR, Bioorg. Med. Chem. 13 (2005), pp. 237–255. doi:https://doi.org/10.1016/j.bmc.2004.09.039.
   PubMed Web of Science ®Google Scholar
• S.P. Gupta and S. Kumaran, A quantitative structure–activity relationship study on some series of anthranilic acid-based matrix metalloproteinase inhibitors, Bioorg. Med. Chem. 13 (2005), pp. 5454–5462. doi:https://doi.org/10.1016/j.bmc.2005.05.055.
   PubMed Web of Science ®Google Scholar
• S.P. Gupta and S. Kumaran, Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: Bicyclic heteroaryl hydroxamic acid analogs, Lett. Drug Des. Discov. 2 (2005), pp. 522–528. doi:https://doi.org/10.2174/157018005774479096.
   Web of Science ®Google Scholar
• S.P. Gupta and S. Kumaran, Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: Piperazine, piperidine and diazepine hydroxamic acid analogs, Asian J. Biochem. 1 (2006), pp. 211–223. doi:https://doi.org/10.3923/ajb.2006.211.223.
   Google Scholar
• S.P. Gupta and S. Kumaran, Quantitative structure-activity relationship studie s on benzodiazepine hydroxamic acid inhibitors of matrix metalloproteinases an d tumor necrosis factor-α converting enzyme, Asian J. Biochem. 1 (2006), pp. 47–56. doi:https://doi.org/10.3923/ajb.2006.47.56.
   Google Scholar
• M. Fernández and J. Caballero, QSAR modeling of matrix metalloproteinase inhibition by N-hydroxy-alpha-phenylsulfonylacetamidederivatives, Bioorg. Med. Chem. 15 (2007), pp. 6298–626310. doi:https://doi.org/10.1016/j.bmc.2007.06.014.
   PubMed Web of Science ®Google Scholar
• T. Jha, N. Adhikari, A. Saha, and S.A. Amin, Multiple molecular modelling studies on some derivatives and analogues of glutamic acid as matrix metalloproteinase-2 inhibitors, SAR QSAR Environ. Res. 29 (2018), pp. 43–68. doi:https://doi.org/10.1080/1062936X.2017.
   PubMed Web of Science ®Google Scholar
• N. Adhikari, S.A. Amin, A. Saha, and T. Jha, Exploring in house glutamate inhibitors of matrix metalloproteinase-2 through validated robust chemico-biological quantitative approaches, Struct. Chem. 29 (2018), pp. 285–297. doi:https://doi.org/10.1007/s11224-017-1028-6.
   Web of Science ®Google Scholar
• A.K. Halder, A. Saha, and T. Jha, Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase-2 inhibitors, J. Pharm. Pharmacol. 65 (2013), pp. 1541–1554. doi:https://doi.org/10.1111/jphp.12133.
   PubMed Web of Science ®Google Scholar
• N. Adhikari, S.A. Amin, A. Saha, and T. Jha, Structural exploration for the refinement of anticancer matrix metalloproteinase-2 inhibitor designing approaches through robust validated multi-QSARs, J. Mol. Struct. 1156 (2018), pp. 501–515. doi:https://doi.org/10.1016/j.molstruc.2017.12.005.
   Web of Science ®Google Scholar
• S. Sanyal, S.A. Amin, N. Adhikari, and T. Jha, QSAR modelling on a series of arylsulfonamide-based hydroxamates as potent MMP-2 inhibitors, SAR QSAR Environ. Res. 30 (2019), pp. 247–263. doi:https://doi.org/10.1080/1062936X.2019.1588159.
   PubMed Web of Science ®Google Scholar
• S. Mondal, S. Banerjee, S.A. Amin, and T. Jha, Structural analysis of arylsulfonamide-based carboxylic acid derivatives: A QSAR study to identify the structural contributors toward their MMP-9 inhibition, Struct. Chem. 32 (2021), pp. 417–430. doi:https://doi.org/10.1007/s11224-020-01635-4.
   Web of Science ®Google Scholar